Merging two companies and securing a €75m ($81m) series A venture round is not an unimpressive achievement, particularly when the combined group is yet to achieve proof of concept, and is active in the tricky and competitive arena of immunology. But Calluna Pharma emerged last week in just this manner, and has given itself three years to prove its pipeline’s value.
Key Takaways
- Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma
Calluna does have a bit of a leg-up in that its CEO John Montana, is, in addition to his duties...
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
